Enfortumab vedotin Active Not Recruiting Phase 2 Trials for Metastatic Urothelial Cancer Treatment

Active Not RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04995419A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy